No abstract

No abstract

TX 75083-3836 U.S.A., fax 01-972-952-9435. AbstractMaximizing production is a common challenge that haunts the oil industry more today than it ever has. Shrinking reserves, environmental concerns and higher costs means we have to be more aggressive and efficient at draining our reservoirs. Completion studies have proven to be a valuable tool in maximizing production, however these studies often fail to take into account significant reservoir variables. To help understand the Ammo (Ammunition) Field Granite Wash in Washita County, Oklahoma, a study was performed looking at well variables to characterize the reservoir as well as determine the most efficient completion strategy. In this way, the reservoir variables were able to be quantified so offset productions and treatments could be compared with a high degree of confidence. This paper examines a data set of wells using data compiled from core data, reservoir geology, drilling, completion, and production records maintained by the oil company. Stimulation records from the service company were then added as well as formation and calculated fracture properties. Drawdown production analysis techniques and non-Darcy flow effects were modeled to gauge frac halflengths.Graphical techniques were then utilized with reservoir and treatment data to identify trends and anomalies.

No abstract

Vascular endothelial growth factor receptor 2 (VEGFR2), a key regulator of tumor angiogenesis, is highly expressed across numerous tumor types and has been an attractive target for anti-cancer therapy. However, clinical application of available VEGFR2 inhibitors has been challenged by limited efficacy and a wide range of side effects, potentially due to inadequate selectivity for VEGFR2. Thus, development of potent VEGFR2 inhibitors with improved selectivity is needed. Rivoceranib is an orally administered tyrosine kinase inhibitor that potently and selectively targets VEGFR2. A comparative understanding of the potency and selectivity of rivoceranib and approved inhibitors of VEGFR2 is valuable to inform rationale for therapy selection in the clinic. Here, we performed biochemical analyses of the kinase activity of VEGFR2 and of a panel of 270 kinases to compare rivoceranib to 10 FDA-approved kinase inhibitors (“reference inhibitors”) with known activity against VEGFR2. Rivoceranib demonstrated potency within the range of the reference inhibitors, with a VEGFR2 kinase inhibition IC50 value of 16 nM. However, analysis of residual kinase activity of the panel of 270 kinases showed that rivoceranib displayed greater selectivity for VEGFR2 compared with the reference inhibitors. Differences in selectivity among compounds within the observed range of potency of VEGFR2 kinase inhibition are clinically relevant, as toxicities associated with available VEGFR2 inhibitors are thought to be partly due to their effects against kinases other than VEGFR2. Together, this comparative biochemical analysis highlights the potential for rivoceranib to address clinical limitations associated with off-target effects of currently available VEGFR2 inhibitors.